QSA congratulates Autolus for achieving its historic milestone dosing the first patient with its pioneering BOBCAT trial of obecabtagene autoleucel (obe-cel), a ‘one-time’ immunotherapy treatment for progressive multiple sclerosis (PMS). QSA is providing advanced imaging analytics in support of this groundbreakig work.

QSA and UCL have launched a joint initiative to educate medical professionals and patients about amyloid-related imaging abnormalities (ARIA), a key unmet need in dementia healthcare. Collaborating with industry leaders and third sector organisations, QSA and UCL have developed an online resource of self-guided and interactive educational materials specifically for this topic. The website is a dynamic resource hub including everything from ARIA biology, to how ARIA is monitor

QSA Co-Founder Dr. Frederik Barkhof (Chair of Neuroradiology in the UCL Queen Square Institute of Neurology at University College London) recently published the paper “ Are we ready for amyloid-related imaging abnormalities (ARIA) monitoring? A European survey among neuroradiologists and neurologists by the ESNR/EAN Working Group ” in European Radiology: “ The European Society of Neuroradiology (ESNR)/European Academy of Neurology (EAN) ARIA Working Group conducted a survey t

QSA announced the results of its research project into Multiple Sclerosis subtyping which was recently published in the journal Brain :   MS is not one disease and current subtypes fail to describe the underlying tissue changes, which we need to know to treat it. The study was led joinly by Charles Wilard and Lemuel Puglisi from Queen Square Analytics.  “By using an AI model combined with a highly available blood marker with MRI, we have been able to show two clear biological